Trial Profile
A Phase I Study of Pevonedistat (TAK-924) and Decitabine Combination Therapy in High Risk Acute Myeloid Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Pevonedistat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 06 Mar 2024 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.
- 06 Mar 2024 Planned primary completion date changed from 15 Dec 2023 to 15 Dec 2024.
- 03 Jul 2023 Planned End Date changed from 15 Jun 2023 to 15 Dec 2023.